Latest IPO / New Life Science Listings

NurExone Biologic Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility

April 25
Last Trade: 0.50 0.02 4.17

TORONTO and HAIFA, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company is pleased to announce that its common shares are now quoted for trading on the OTCQB® Venture Market (the "OTCQB") under the symbol NRXBF. The OTCQB listing enhances visibility and facilitates trading by US institutional and retail investors. As the sole...Read more

Mobile-health Network Solutions Makes History as First APAC Telehealth Company Listed on US Stock Exchange

April 15
Last Trade: 1.80 0.00 0.00

SINGAPORE, April 15, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR), a pioneering Asia-Pacific (APAC) telehealth provider, celebrates its successful initial public offering (IPO) on the Nasdaq stock exchange. This achievement marks MNDR as the first pure-play telehealth company from APAC to list on a major US stock exchange. “This IPO is a significant achievement for MNDR and reflects the surging demand for...Read more

Skye Bioscience Uplists to The Nasdaq Global Market

April 10
Last Trade: 12.06 0.00 0.00

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with an emphasis on obesity and ocular indications, announced today that the Company has received approval to list its common stock on the Nasdaq Global...Read more

Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024

April 3
Last Trade: 3.90 0.04 1.04

Company's Listing Application Approved by Nasdaq VICTORIA, BC, April 3, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that the Company's common shares have been approved for listing on the Nasdaq...Read more

Auna Raises US$360 Million in Gross Proceeds via NYSE IPO, Marking Its Debut in the International Equity Markets

March 22
Last Trade: 8.21 0.00 0.00

Auna’s mission is to transform healthcare in Latin America, providing access to a highly integrated offering of quality healthcare services in Spanish-speaking Americas. Auna has built one of Latin America´s largest modern healthcare platforms, with presence in Mexico, Colombia and Peru. 2023 revenues of US$1.05 billion and Adjusted EBITDA of US$223 million, up 58% and 90%, respectively, with Adjusted EBITDA margin expanding to...Read more

Alto Neuroscience Announces Pricing of Upsized Initial Public Offering

February 1
Last Trade: 12.92 0.00 0.00

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds to Alto from the offering are expected to be approximately $128.6 million before deducting underwriting discounts and commissions and other offering expenses payable by Alto. In...Read more

Concord Medical Services Announces Listing of Its Subsidiary on The Stock Exchange of Hong Kong Limited

January 9
Last Trade: 0.67 0.08 13.42

BEIJING, Jan. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced the listing of a minority stake of 39,420,200 H shares in Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), its subsidiary, at an initial public offer price of HK$14.28 per H share...Read more

Medicenna Therapeutics Announces Trading on the OTCQB Under the Symbol MDNAF

December 19
Last Trade: 2.36 0.02 0.85

TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that its shares will commence trading on the OTCQB Venture Market in the United States, effective December 19, 2023. Medicenna’s shares will continue to trade on the Toronto Stock Exchange...Read more

Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...